233 related articles for article (PubMed ID: 35395704)
1. Metabolic Intervention Nanoparticles for Triple-Negative Breast Cancer Therapy via Overcoming FSP1-Mediated Ferroptosis Resistance.
Yang J; Jia Z; Zhang J; Pan X; Wei Y; Ma S; Yang N; Liu Z; Shen Q
Adv Healthc Mater; 2022 Jul; 11(13):e2102799. PubMed ID: 35395704
[TBL] [Abstract][Full Text] [Related]
2. Multienzyme-like Reactivity Cooperatively Impairs Glutathione Peroxidase 4 and Ferroptosis Suppressor Protein 1 Pathways in Triple-Negative Breast Cancer for Sensitized Ferroptosis Therapy.
Li K; Lin C; Li M; Xu K; He Y; Mao Y; Lu L; Geng W; Li X; Luo Z; Cai K
ACS Nano; 2022 Feb; 16(2):2381-2398. PubMed ID: 35041395
[TBL] [Abstract][Full Text] [Related]
3. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis.
Bersuker K; Hendricks JM; Li Z; Magtanong L; Ford B; Tang PH; Roberts MA; Tong B; Maimone TJ; Zoncu R; Bassik MC; Nomura DK; Dixon SJ; Olzmann JA
Nature; 2019 Nov; 575(7784):688-692. PubMed ID: 31634900
[TBL] [Abstract][Full Text] [Related]
4. Ferroptosis-enhanced chemotherapy for triple-negative breast cancer with magnetic composite nanoparticles.
Zhang J; Zhou K; Lin J; Yao X; Ju D; Zeng X; Pang Z; Yang W
Biomaterials; 2023 Dec; 303():122395. PubMed ID: 37988899
[TBL] [Abstract][Full Text] [Related]
5. FSP1 is a glutathione-independent ferroptosis suppressor.
Doll S; Freitas FP; Shah R; Aldrovandi M; da Silva MC; Ingold I; Goya Grocin A; Xavier da Silva TN; Panzilius E; Scheel CH; Mourão A; Buday K; Sato M; Wanninger J; Vignane T; Mohana V; Rehberg M; Flatley A; Schepers A; Kurz A; White D; Sauer M; Sattler M; Tate EW; Schmitz W; Schulze A; O'Donnell V; Proneth B; Popowicz GM; Pratt DA; Angeli JPF; Conrad M
Nature; 2019 Nov; 575(7784):693-698. PubMed ID: 31634899
[TBL] [Abstract][Full Text] [Related]
6. Simvastatin induced ferroptosis for triple-negative breast cancer therapy.
Yao X; Xie R; Cao Y; Tang J; Men Y; Peng H; Yang W
J Nanobiotechnology; 2021 Oct; 19(1):311. PubMed ID: 34627266
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism.
Li P; Lin Q; Sun S; Yang N; Xia Y; Cao S; Zhang W; Li Q; Guo H; Zhu M; Wang Y; Zheng Z; Li S
Cell Death Dis; 2022 Sep; 13(9):808. PubMed ID: 36130940
[TBL] [Abstract][Full Text] [Related]
8. Disulfiram/Copper Induce Ferroptosis in Triple-Negative Breast Cancer Cell Line MDA-MB-231.
Chu M; An X; Fu C; Yu H; Zhang D; Li Q; Man X; Dai X; Li Z
Front Biosci (Landmark Ed); 2023 Aug; 28(8):186. PubMed ID: 37664913
[TBL] [Abstract][Full Text] [Related]
9. Regulatory network of ferroptosis and autophagy by targeting oxidative stress defense using sulfasalazine in triple-negative breast cancer.
Takatani-Nakase T; Ikushima C; Sakitani M; Nakase I
Life Sci; 2024 Feb; 339():122411. PubMed ID: 38184272
[TBL] [Abstract][Full Text] [Related]
10. Pitavastatin induces autophagy-dependent ferroptosis in MDA-MB-231 cells via the mevalonate pathway.
Tang WJ; Xu D; Liang MX; Wo GQ; Chen WQ; Tang JH; Zhang W
Heliyon; 2024 Mar; 10(5):e27084. PubMed ID: 38444467
[TBL] [Abstract][Full Text] [Related]
11. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells.
Ding Y; Chen X; Liu C; Ge W; Wang Q; Hao X; Wang M; Chen Y; Zhang Q
J Hematol Oncol; 2021 Jan; 14(1):19. PubMed ID: 33472669
[TBL] [Abstract][Full Text] [Related]
12. Au-Fe
Wei R; Fu G; Li Z; Liu Y; Qi L; Liu K; Zhao Z; Xue M
J Colloid Interface Sci; 2024 Jun; 663():644-655. PubMed ID: 38430834
[TBL] [Abstract][Full Text] [Related]
13. Targeted Intervention of NF2-YAP Signaling Axis in CD24-Overexpressing Cells Contributes to Encouraging Therapeutic Effects in TNBC.
Hou L; Pu L; Chen Y; Bai Y; Zhou Y; Chen M; Wang S; Lv Y; Ma C; Cheng P; Zhang K; Liang Q; Deng S; Wang D
ACS Nano; 2022 Apr; 16(4):5807-5819. PubMed ID: 35420780
[TBL] [Abstract][Full Text] [Related]
14. A self-assembly nano-prodrug for triple-negative breast cancer combined treatment by ferroptosis therapy and chemotherapy.
Chen Y; Yao Z; Liu P; Hu Q; Huang Y; Ping L; Zhang F; Tang H; Wan T; Ping Y; Li B
Acta Biomater; 2023 Mar; 159():275-288. PubMed ID: 36709836
[TBL] [Abstract][Full Text] [Related]
15. Photothermal Ferrotherapy - Induced Immunogenic Cell Death via Iron-Based Ternary Chalcogenide Nanoparticles Against Triple-Negative Breast Cancer.
Wu Q; Li Z; Zhou X; Wei Z; Ramadan S; Xu Y; Xu L; Li D
Small; 2024 May; 20(20):e2306766. PubMed ID: 38095479
[TBL] [Abstract][Full Text] [Related]
16. PGRMC1 promotes triple-negative breast cancer cell growth via suppressing ferroptosis.
Zhao Y; Ruan X; Cheng J; Xu X; Gu M; Mueck AO
Climacteric; 2023 Apr; 26(2):135-142. PubMed ID: 36724820
[TBL] [Abstract][Full Text] [Related]
17. Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer.
Wang Y; Sun Y; Wang F; Wang H; Hu J
Biomed Pharmacother; 2023 Dec; 169():115866. PubMed ID: 37951026
[TBL] [Abstract][Full Text] [Related]
18. Unleashing Ferroptosis in Human Cancers: Targeting Ferroptosis Suppressor Protein 1 for Overcoming Therapy Resistance.
Lee J; Roh JL
Antioxidants (Basel); 2023 Jun; 12(6):. PubMed ID: 37371948
[TBL] [Abstract][Full Text] [Related]
19. Eupaformosanin induces apoptosis and ferroptosis through ubiquitination of mutant p53 in triple-negative breast cancer.
Wei Y; Zhu Z; Hu H; Guan J; Yang B; Zhao H
Eur J Pharmacol; 2022 Jun; 924():174970. PubMed ID: 35469839
[TBL] [Abstract][Full Text] [Related]
20. Diselenium-linked dimeric prodrug nanomedicine breaking the intracellular redox balance for triple-negative breast cancer targeted therapy.
Chen M; Zhang M; Lu X; Li Y; Lu C
Eur J Pharm Biopharm; 2023 Dec; 193():16-27. PubMed ID: 37865134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
